Health & Biotech
Biotron hits 20-bagger status then plunges into the red as profit-takers exit
Bod discovers cannabis edibles, says clinical trial proves they work
Pot stock eSense is soaring on UK deal but two others may have fallen over
Canada legalises pot this week – here are the ASX stocks that could benefit
Novita gets ready for US launch of attention deficit disorder tool
Cannabis play MMJ sells down Harvest One stake and THC changes its name
Green lights across the board for AuMake ahead of formula launch
Cannabis stocks just got a big boost with UK legalisation of medical cannabis
What to look for when investing in ASX wellness and dietary supplements stocks
NextLeaf is the latest Aussie pot listing to head for Canada – not the ASX
It’s a fresh look for Total Face Group, with new CEO and acquisition
MGC Pharma’s cannabis-based epilepsy treatment approved for Australian patient sales
Pharmaxis gets another fatty liver drug through clinical trials; shares gain
Weed week: it’s reefer madness as global pot stocks pass $6b in fund raising
Bioplastics play Secos Group places health subsidiary under review
Revolving doors spin at Monash IVF as CEO quits for personal reasons
The United Nations might soon give its blessing to a key marijuana ingredient
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.